Cross-linking of IgE antibodies bound to monocyte and macrophage FcεRs by tumour-associated antigens (TAAs), displays evidence of a two-armed antitumour mechanism for IgE: first, through monocyte and macrophage-mediated tumour cell killing, and second by repolarisation of tumour-supportive M2-like TAM subsets, through enhancement of proinflammatory and immunostimulatory activity (Figure 1). This evidence concerns the gene IGHE and neoplasm.